Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA II long-term open-label extension of PF-00547659 in Crohn's disease
NL-OMON43920Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ontamalimab in Crohn's disease and inflammatory bowel disease (IBD), sponsored by Pfizer. Primary endpoint: On-treatment adverse events. Started Jun 2012; status: active, not recruiting.
02
Drugs
ontamalimab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON43920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43920.